First Tracks Biotherapeutics Inc
TRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.11B
Close$
$6.45
81.3% downside
Current Fair Value
81.3% downsideOvervalued by 81.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.11 Billion |
|---|---|
| Enterprise Value | $947.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 3.37 |
| Outstanding Shares | 35,390,679 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -13.33 |
|---|---|
| PEG | 45.5 |
| Price to Sales | - |
| Price to Book Ratio | 8.62 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$75.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
104 employees
CEO: Daniel R. Faga First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory...